Nathan Fowler
Nathan Fowler/LinkedIn

Nathan Fowler: BostonGene’s AI Platform Drives a Paradigm Shift in Cancer

Nathan Fowler, Chief Medical Officer at Bostongene, shared a post on LinkedIn about a paper he co-authored with colleagues published in Human Genetics:

“Using AI to interpret RNA findings will change the game in cancer. BostonGene AI Platform published today in Human Genetics!

Technology like this is leading to a paradigm shift in how we approach drug development.”

Title: MutAnt – mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics

Authors: Aleksandr Sarachakov, Anastasiya Yudina, Viktor Svekolkin, Anna Parfenenkova, Miryam Spektor, Polina Oshchepkova, Marina Pak, Zoia Antysheva, Linda Balabanian, Jessica H. Brown, Max Feinberg, Nathan Fowler, Alexander Bagaev

You can read the full article in Human Genetics.

Nathan Fowler: BostonGene’s AI Platform Drives a Paradigm Shift in Cancer